From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona has a sizable and rapidly growing bioscience industry. State bioscience firms employed 25,686 in 2016 in 1,310 individual business establishments. Industry employment has grown by 9 percent since 2014, twice the growth rate of the nation, with four of the five major subsectors adding jobs during the period. Both drugs and pharmaceuticals and research, testing and medical labs have experienced double-digit job growth since 2014. Arizona inventors have been awarded nearly 2,000 bioscience-related patents since 2014, among the second quintile of states in patent activity. Since 2015, NIH awards to Arizona institutions have increased, reaching $189 million in FY 2017. (Get The Facts)
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today unveiled a strategic plan that will guide its policy and advocacy activities to help the U.S. medical technology industry maintain its global competitive edge and to encourage innovation.
Arizona’s future is tied to the strength of its leadership. The Flinn-Brown Civic Leadership Academy, a nonpartisan program sponsored by the Flinn Foundation and the Thomas R. Brown Foundations is helping to train tomorrow’s civic leaders and now is the time to apply for the Fall program.
Approval of HDE Will Allow Up to 4,000 U.S. Patients Not Eligible for Transplant to Receive the Total Artificial Heart on a Permanent Basis
“The unparalleled sensitivity, accuracy, and reproducibility offered by the Abscription®-based G-CIMP test, coupled with its ability to efficiently assess multiple methylation biomarkers in FFPE patient samples, makes this the best in class option for prognostic glioma testing.”
- TENWEST Impact Festival
- 10/11/2019 - 10/20/2019
- BIO Investor Forum 2019
- 10/22/2019 - 10/23/2019
- San Francisco
- Women’s Angel Investor Forum
- Mini-Medical School - Flinn Foundation Buffmire Lecture
- KOL Luncheon: Breast Cancer Molecular Diagnostics